A comparative study of Vildagliptin�Metformin versus Glimepiride�Metformin therapy in type 2 diabetes mellitus at a tertiary hospital of North India

Dr Avtar Singh Dhanju; Dr Ajay Chhabra; Dr Chinky Mahajan; Dr Pritam Singh Sandhu

Volume : VI, Issue : V, May - 2016

A comparative study of Vildagliptin�Metformin versus Glimepiride�Metformin therapy in type 2 diabetes mellitus at a tertiary hospital of North India

Dr Avtar Singh Dhanju, Dr Ajay Chhabra, Dr Chinky Mahajan, Dr Pritam Singh Sandhu

Abstract :

Diabetes mellitus (DM) is one of the most common chronic disorders attaining epidemic proportions worldwide. There are different classes of drugs available to treat it. The present study was undertaken to study comparison between vildagliptin–metformin combination versus glimepiride–metformin combination. Aims and objectives: To compare the efficacy of vildagliptin with glimepiride as an add–on therapy to metformin in patients of type–2 diabetes mellitus in terms of glycemic control parameters like fasting blood glucose, 2 hour postprandial glucose and reduction in HbA1C levels from baseline and to compare the tolerability and development of side effects in patients on vildagliptin–metformin therapy versus those on glimepiride–metformin therapy. Materials and methods: This comparative study was conducted on 100 type 2 diabetes mellitus patients at Government Medical College, Amritsar. Half of them were put on vildagliptin–metformin and the other half was given glimepiride–metformin. Blood sugar levels, HbA1c were measured serially and the data tabulated and analysed statistically. Conclusion: It was seen that vildagliptin and glimepiride were equally efficacious in reducing fasting plasma glucose when given as add–on to metformin. However HbA1c control was better in vildagliptin–metformin group. Incidence of hypoglycaemia was much less in same group. As far as weight change was concerned, vildagliptin–metformin combination led to weight loss while weight gain was seen with glimepiride–metformin combination.